• Vaccine Name: L. T -HIV-1 Gag
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004629
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Gag from HIV 1 gene engineering:
  • Type: Recombinant vector construction
  • Description: A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001028
• Preparation: A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: Balb/c
• Vaccine Immune Response Type: VO_0003057
• Immune Response: Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag (Breton et al., 2007).
• Efficacy: Immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection (Breton et al., 2007).